Crucial requirement for standardization during the development of novel recombinant BCG vaccines: Does the corresponding substrain background matter?
Open Access
- 25 July 2016
- journal article
- editorial
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (12) , 3099-3102
Abstract
The Bacillus Calmette-Guerin (BCG) vaccine is not a single organism, but consists of substrains that vary in genotypes and phenotypes. Actually, BCG is the common name given to a family of vaccines created in 1921 by the in vitro attenuation of a virulent Mycobacterium bovis in France. Even nearly a century of use, the BCG vaccine lingers generating confusion and debate due to its diversity and failure to protect against tuberculosis (TB). That is probably owing to the enduring lack of standardization during production, distribution and administration procedures. Since the 1940s, substantial sequence modifications among the BCG substrains have been described. To increase the level of complexity, even though that the prolific generation of recombinant BCG vaccines has been promising, the relationships between those candidates used in current clinical trials and their parental substrains are either unsatisfactorily connected or have been never fully delineated. Consequently, the use of the most protective BCG substrain as the background or platform in the development of all recombinant BCG vaccine candidates has not been standardized. In order to schematize and to clarify the subject regarding substrains commonly used to generate those novel vaccines, a sequential emergence of the parental BCG vaccine substrains and their matching recombinant ones, if any, was built. Hence, for a total of 24 BCG substrains currently in circulation worldwide, 9 have been used to sustain one or more genetic modifications, resulting in around 21 novel recombinant BCG vaccines. Although this is a remarkable success, only 2 out of the 21 recombinant BCG substrains harbor a background representative of the most immunogenic group. Systematizing the novel BCG vaccines and their parental strains may facilitate our understanding of protection provided by BCG immunizations.Keywords
This publication has 11 references indexed in Scilit:
- Tuberculosis Vaccines – state of the art, and novel approaches to vaccine developmentInternational Journal of Infectious Diseases, 2015
- The fbpA/sapM Double Knock Out Strain of Mycobacterium tuberculosis Is Highly Attenuated and Immunogenic in MacrophagesPLOS ONE, 2012
- Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs)Journal of the Formosan Medical Association, 2011
- Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccinationVaccine, 2010
- New vaccines against tuberculosis: lessons learned from BCG immunisation in BrazilTransactions of the Royal Society of Tropical Medicine and Hygiene, 2008
- Mycobacterium bovis BCG Vaccines Exhibit Defects in Alanine and Serine CatabolismInfection and Immunity, 2003
- An Analysis of Some Hypotheses Related to the Chingelput Bacille Calmette-Guérin TrialClinical Infectious Diseases, 2000
- A historical and molecular phylogeny of BCG strainsVaccine, 1999
- BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics.1984
- The virulence of some strains of BCG for golden hamsters. Further studies.1970